Buy Rating Reaffirmed for Gossamer Bio on Seralutinib’s Promising Clinical Data and Future Prospects

Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Gossamer Bio (GOSS – Research Report), retaining the price target of $10.00.

Patrick Trucchio has given his Buy rating due to a combination of factors surrounding the promising clinical data of Gossamer Bio’s lead program seralutinib, an inhaled tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The updated Phase 2 trial data, presented at a recent conference, indicates that seralutinib has shown consistent and durable improvement in pulmonary vascular resistance (PVR) without introducing new safety concerns. This suggests a persistent therapeutic effect, which is particularly relevant as it aligns with the patient subset targeted in the forthcoming Phase 3 trial expected to conclude in 4Q25. Trucchio reasserts his Buy rating and a price target of $10, anticipating further updates that will likely reinforce the positive outlook on Gossamer Bio’s shares.
Furthermore, the robustness of seralutinib’s pharmacological profile is highlighted by its performance during the open-label extension period of the trial, showing a significant median change in PVR and a decrease in the incidence of treatment-emergent adverse events, particularly cough, which is a common side effect. Given the consistency of the results with previous data readings and the potential for a favorable safety profile, the analyst expresses confidence in the drug’s prospects. Trucchio’s valuation also takes into account a comprehensive analysis using discounted cash flow and sum-of-the-parts methodologies, reflecting a substantial probability of success in both PAH and other potential indications. He acknowledges risks such as clinical development and commercialization but maintains a positive stance on the investment potential of Gossamer Bio.

In another report released on May 8, Wedbush also maintained a Buy rating on the stock with a $4.00 price target.

Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GOSS in relation to earlier this year.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Gossamer Bio (GOSS) Company Description:

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate is GB001, which is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi in 2015 and is headquartered in San Diego, CA.